Drug
Omidenepag isopropyl clinical trials
Also written DE-117.
- studies test it
- 12
- open now
- 0
- in phase 3
- 6
- first study started
- 2012
How studies write it
Studies that test it under each name
Development codes
Combined with it in one product
Studies by the year they started
12 studies that test it; most in 2018 (3)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 3 |
| 2019 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 5
- Phase 3
- 6
- Phase 4
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 0
Santen Inc. (7) · Santen Pharmaceutical Co., Ltd. (4) · Santen Pharmaceutical Asia Pte. Ltd. (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses omidenepag isopropyl is read from its arms, and is right about nine times in ten.
Testing it · 12
- A Phase III Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Compared With Latanoprost Ophthalmic Solution in Subjects With OAG or OHTCompletedPhase 3Santen Pharmaceutical Co., Ltd.NCT02981446Written as DE-117
- A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 3 StudyCompletedPhase 3Santen Inc.NCT03691649Written as DE-117 Ophthalmic Solution
- DE-117 Spectrum 5 StudyCompletedPhase 3Santen Inc.NCT03697811Written as DE-117 Ophthalmic Solution
- A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 4 StudyCompletedPhase 3Santen Inc.NCT03691662Written as DE-117 Ophthalmic Solution
- Study in Prostaglandin Associated Peri-orbitopathy Switching From Prostaglandin Monotherapy to Omidenepag IsopropylStatus unknownPhase 4Santen Pharmaceutical Asia Pte. Ltd.NCT05279716Written as Eybelis ophthalmic solution 0.002%
- Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Once Daily and Twice Daily in Subjects With Primary Open-Angle Glaucoma SPECTRUM 6CompletedPhase 2Santen Inc.NCT03858894Written as DE-117 Ophthalmic Solution QD
- Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular HypertensionCompletedPhase 2Santen Inc.NCT01868126Written as DE-117 ophthalmic solution
- A Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHTCompletedPhase 1/2Santen Inc.NCT01654484Written as DE-117
- Multi-center Phase II Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular HypertensionCompletedPhase 2Santen Inc.NCT02179008Written as DE-117 Low Dose ophthalmic solution
- A Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension -AYAME Study-CompletedPhase 2/3Santen Pharmaceutical Co., Ltd.NCT02623738Written as DE-117 ophthalmic solution low
- A Study Assessing the Safety and Efficacy of DE-117 in Subjects With POAG or OH Who Are Non-/Low-responders to Latanoprost: FUJI StudyCompletedPhase 3Santen Pharmaceutical Co., Ltd.NCT02822742Written as DE-117 ophthalmic solution
- A Pharmacokinetic Study of DE-117 Ophthalmic Solution in Healthy Adult Male Subjects - Phase I Study -CompletedPhase 1Santen Pharmaceutical Co., Ltd.NCT02650063Written as DE-117
Given in every arm · 1 — omidenepag isopropyl is usual care beside what is tested
Codes
What other systems call omidenepag isopropyl · ClinicalTrials.gg INT001139
- MeSH (NLM) C000632951omidenepag isopropylOne source NLM
- UNII (FDA) G0G0H52U6KOMIDENEPAG ISOPROPYLConfirmed FDA, NLM, Wikidata
- RxNorm 2612690One source FDA
- Wikidata Q27896252omidenepag isopropylConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C170254Omidenepag IsopropylOne source FDA
- DrugBank DB15071One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000632951 | omidenepag isopropyl | One source NLM |
| UNII (FDA) | G0G0H52U6K | OMIDENEPAG ISOPROPYL | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2612690 | — | One source FDA |
| Wikidata | Q27896252 | omidenepag isopropyl | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C170254 | Omidenepag Isopropyl | One source FDA |
| DrugBank | DB15071 | — | One source Wikidata |
Also registered as omidenepag (UNII Z95F9F9LU4 · RxNorm 2612691).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.